Hims & Hers Health Inc (FRA:82W)
€ 18.355 -0.035 (-0.19%) Market Cap: 4.17 Bil Enterprise Value: 3.95 Bil PE Ratio: 254.50 PB Ratio: 12.19 GF Score: 57/100

Q3 2024 Hims & Hers Health Inc Earnings Call Transcript

Nov 04, 2024 / 10:00PM GMT
Release Date Price: €18.36 (-0.19%)

Key Points

Positve
  • Hims & Hers Health Inc (HIMS) reported a 77% year-over-year revenue increase, reaching $401.6 million in the third quarter.
  • The company surpassed $50 million in adjusted EBITDA, reflecting a 13% adjusted EBITDA margin.
  • The subscriber base grew by 44% year over year, with over 2 million subscribers by the end of the third quarter.
  • Hims & Hers Health Inc (HIMS) has successfully expanded its personalized solutions, with over 1 million consumers benefiting from these offerings.
  • The company is making significant strides in democratizing access to high-quality, personalized healthcare solutions at mass market prices.
Negative
  • Gross margin declined by 2 points quarter over quarter to 79%, primarily due to the scaling of the weight loss specialty.
  • There is ongoing pressure from gross margin headwinds associated with new product launches.
  • The company anticipates continued gross margin degradation in the fourth quarter as the weight loss specialty gains traction.
  • Marketing expenses remain high, accounting for 45% of revenue, although this marks an improvement from previous quarters.
  • The regulatory landscape for GLP-1 solutions remains uncertain, posing potential challenges for future growth.
Operator

Ladies and gentlemen, thank you for standing by. My name is Krista and I will be your conference operator today. At this time, I would like to welcome everyone to His & Hers third-quarter earnings conference call. (Operator Instructions)

I would now like to turn the conference over to Bill Newby, Head of Investor Relations.

Bill, you may begin.

Bill Newby
Hims & Hers Health Inc - Senior Director, Investor Relations

Good afternoon, everyone, and welcome to the His & Hers Health third-quarter 2024 earnings call. Today, after the market closed, we released this quarter's shareholder letter, a copy of which you can find on our website at investors.hims.com. On the call with me today is Andrew Dudum, our Co-Founder and Chief Executive Officer; Yemi Okupe, our Chief Financial Officer; and Dr. Patrick Carroll, our Chief Medical Officer.

Before I hand it over to Andrew, I need to remind you of legal, Safe Harbor, and cautionary declarations. Certain statements and projections of future results made in this presentation

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot